AstraZeneca Announces Approval of Soliris in China

AstraZeneca announced that Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is a first-in-class C5 complement inhibitor that works by inhibiting the C5 protein in the terminal complement cascade, a component of the body's immune system. By targeting this pathway, Soliris helps to control the uncontrolled activation of the complement system, which can lead to the body attacking its own healthy cells. Soliris, a medication, has been granted approval by the National Medical Products Administration (NMPA) in China, based on the results obtained from the Phase III REGAIN trial. The trial provided comprehensive results showing the clinical benefit of Soliris for patients with anti-AChR antibody-positive generalised myasthenia gravis (gMG). These patients had previously not responded to immunosuppressive treatment and still experiencing significant unresolved symptoms of the disease. Soliris has been approved in several countries, including the United States, European Union, Japan, and China, for the treatment of various conditions. The approval of Soliris marks a significant milestone for the generalised myasthenia gravis (gMG) community in China, providing with a targeted treatment option that has substantial clinical data and extensive real-world evidence which improves the ability to carry out daily activities and enhances the overall quality of life for patients.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!